Gene expression patterns in livers of Hispanic patients infected with hepatitis C virus

Autoimmunity

Volumn 44, Issue 7, 2011, Pages 532-542

  Hevezi, Peter A ^a,c   Tom, Edward ^a,d   Wilson, Keith ^a   Lambert, Peter ^a   Gutierrez Reyes, Gabriela ^b   Kershenobich, David ^b   Zlotnik, Albert ^a,c  

^a Facet Biotech   (United States)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Veracyte Inc   (United States)

Author keywords

Gene expression; Hepatitis C; Microarrays

Indexed keywords

ADENOSINE DEAMINASE, RNA SPECIFIC; ALPHA INTERFERON; CANCER SUSCEPTIBILITY CANDIDATE 5; CASEIN KINASE IEPSILON; CCAAT ENHANCER BINDING PROTEIN; CD47 ANTIGEN; CHEMOKINE CXCL 10; CLATHRIN INTERACTOR 1; CYTIDINE PHOSPHATE; DEAD BOX POLYPEPTIDE 60; ECTONUCLEOTIDE PYROPHOSPHATASE 2; EPITHELIAL CELL ADHESION MOLECULE; FIBRONECTIN 3A; FYVE, RHOGEF AND PH DOMAIN CONTAINING 4; GLYPICAN 3; GROWTH ARREST AND DNA DAMAGE INDUCIBLE BETA; GROWTH ARREST AND DNA DAMAGE INDUCIBLE GAMMA; GS HOMEOBOX 1; HECT DOMAIN AN RLD 6; INTERFERON INDCUCED PROTEIN 44; INTERFERON INDUCED PROTEIN WITH TETRATRICOPEPTIDE REPEAT 1; NUCLEAR RECEPTOR COACTIVATOR 2; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PROTEIN; PTC7 PROTEIN PHOSPHATASE; RA B12, MEMBER RAS ONCOGENE FAMILY; RECEPTOR INTERACTING PROTEIN 140; SERUM AMYLOID A; UNCLASSIFIED DRUG; UNINDEXED DRUG; XIAP ASSOCIATED FACTOR 1;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CELL TRANSPORT; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; GENE INDUCTION; HEPATITIS C; HEPATITIS C VIRUS; HISPANIC; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFLAMMATION; LIVER; LIVER BIOPSY; MALE; NEOPLASM; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; BIOPSY; FEMALE; GENE EXPRESSION REGULATION, VIRAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HISPANIC AMERICANS; HUMANS; INTERFERON-ALPHA; MALE; MEXICO; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBAVIRIN; RNA, MESSENGER; YOUNG ADULT;

EID: 80053989850     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2011.592881     Document Type: Article

References (67)

1. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341(8):556-562. (Pubitemid 29384163)
2. McHutchison JG Bacon BR. Chronic hepatitis C: An age wave of disease burden. Am J Manag Care 2005;11(Suppl. 10):S286-S295, quiz S307-S311 (Pubitemid 41552219)
3. Thomson BJ, Finch RG. Hepatitis C virus infection. Clin Microbiol Infect 2005;11(2):86-94. (Pubitemid 40253812)
4. Zhao S, Liu E, Chen P, Cheng D, Lu S, Yu Q,Wang Y,Wei K, Yang P. A comparison of peginterferon alpha-2a and alpha-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials. Clin Ther 2010;32(9): 1565-1577. 540 P. A. Hevezi et al.
5. Teoh NC, Farrell GC, Chan HL. Individualisation of antiviral therapy for chronic hepatitis C. J Gastroenterol Hepatol 2010; 25(7):1206-1216.
6. Zeuzem S, Poordad F. Pegylated-interferon plus ribavirin therapy in the treatment of CHC: Individualization of treatment duration according to on-treatment virologic response. Curr Med Res Opin 2010;26(7):1733-1743.
7. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, Cavalletto L, Schvarcz R, Ideo G, Alberti A. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 1997;26(5): 961-966. (Pubitemid 27242584)
8. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. Hepatology 1997;26(2):473-477. (Pubitemid 27328328)
9. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, Nelson KE, Strathdee SA, Johnson L, Laeyendecker O, Boitnott J, Wilson LE, VlahovD. The natural history of hepatitis C virus infection: Host, viral, and environmental factors. JAMA 2000;284(4):450-456. (Pubitemid 30484478)
10. Chayama K, Hayes CN, Yoshioka K, Moriwaki H, Okanoue T, Sakisaka S, Takehara T, Oketani M, Toyota J, Izumi N, Hiasa Y, Matsumoto A, Nomura H, Seike M, Ueno Y, Yotsuyanagi H, Kumada H. Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C. J Gastroenterol 2011;46(4): 545-555.
11. Izumi N, Asahina Y, Kurosaki M. Predictors of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors. Hepat Res Treat 2010;:703602-703609.
12. Li QZ, Karp DR, Quan J, Branch VK, Zhou J, Lian Y, Chong BF,Wakeland EK, Olsen NJ. Risk factors for ANA positivity in healthy persons. Arthritis Res Ther 2011;13(2):R38.
13. Duma D, Collins JB, Chou JW, Cidlowski JA. Sexually dimorphic actions of glucocorticoids provide a link to inflammatory diseases with gender differences in prevalence. Sci Signal 2010;3(143):ra74.
14. McCaughan GW. Asian perspectives on viral hepatitis: Hepatitis C virus infection. J Gastroenterol Hepatol 2000; 15(Suppl):G90-G93.
15. Iturrino J, Sanchez CJ, Ortiz A, Romero CJ, Velazquez V, Costas P, Torres EA. Outcomes of an underserved Hispanic population with chronic hepatitis C treated with pegylatedinterferon and ribavirin in a government-sponsored clinic. P R Health Sci J 2011;30(1):9-13.
16. Muir AJ, Hu KQ, Gordon SC, Koury K, Boparai N, Noviello S, Albrecht JK, Sulkowski MS, McCone J. Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. J Viral Hepat 2011;18(4):e134-e143.
17. Satapathy SK, Lingisetty CS, Proper S, Chaudhari S, Williams S. Equally poor outcomes to pegylated interferon-based therapy in African Americans and Hispanics with chronic hepatitis C infection. J Clin Gastroenterol 2010;44(2): 140-145.
18. Smith MW, Yue ZN, Korth MJ, Do HA, Boix L, Fausto N, Bruix J, Carithers RL Jr, Katze MG. Hepatitis C virus and liver disease: Global transcriptional profiling and identification of potential markers. Hepatology 2003;38(6):1458-1467. (Pubitemid 37466972)
19. De Giorgi V, Monaco A, Worchech A, Tornesello M, Izzo F, Buonaguro L, Marincola FM,Wang E, Buonaguro FM. Gene profiling, biomarkers and pathways characterizing HCVrelated hepatocellular carcinoma. J Transl Med 2009;7: 85-95.
20. Folkers ME, DelkerDA, Maxwell CI, Nelson CA, Schwartz JJ, Nix DA, Hagedorn CH. ENCODE tiling array analysis identifies differentially expressed annotated and novel 50 capped RNAs in hepatitis C infected liver. PLoS One 2011; 6(2):e14697.
21. Muffak-Granero K, Bueno P, Olmedo C, Comino AM, Hassan L, Garcia-Alcalde F, Serradilla M, Garcia-Navarro A, Mansilla A, Villar JM, Garrote D, Blanco A, Ferron JA. Study of gene expression profile in liver transplant recipients with hepatitis C virus. Transplant Proc 2008;40(9):2971-2974.
22. Okamoto M, Utsunomiya T, Wakiyama S, Hashimoto M, Fukuzawa K, Ezaki T, Hanai T, Inoue H, Mori M. Specific gene-expression profiles of noncancerous liver tissue predict the risk for multicentric occurrence of hepatocellular carcinoma in hepatitis C virus-positive patients. Ann Surg Oncol 2006;13:947-954.
23. Shao RX, Hoshida Y, Otsuka M, Kato N, Tateishi R, Teratani T, Shiina S, Taniguchi H, Moriyama M, Kawabe T, Omata M. Hepatic gene expression profiles associated with fibrosis progression and hepatocarcinogenesis in hepatitis C patients. World J Gastroenterol 2005;11(13):1995-1999. (Pubitemid 40520999)
24. Woodhouse SD, Narayan R, Latham S, Lee S, Antrobus R, Gangadharan B, Luo S, Schroth GP, Klenerman P, Zitzmann N. Transcriptome sequencing, microarray, and proteomic analyses reveal cellular and metabolic impact of hepatitis C virus infection in vitro. Hepatology 2010;52(2):443-453.
25. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162(1):156-159. (Pubitemid 17064313)
26. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:Article 3.
27. Salamov AA, Solovyev VV. Ab initio gene finding in Drosophila genomic DNA. Genome Res 2000;10(4):516-522. (Pubitemid 30259081)
28. Bhaskar V, Law DA, Ibsen E, Breinberg D, Cass KM, DuBridge RB, Evangelista F, Henshall SM, Hevezi P, Miller JC, Pong M, Powers R, Senter P, Stockett D, Sutherland RL, von Freeden-Jeffry U, Willhite D, Murray R, Afar DE, Ramakrishnan V. E-selectin up-regulation allows for targeted drug delivery in prostate cancer. Cancer Res 2003;63(19): 6387-6394. (Pubitemid 37255188)
29. Willis S, Hutchins AM, Hammet F, Ciciulla J, Soo WK, White D, van der Spek P, Henderson MA, Gish K, Venter DJ, Armes JE. Detailed gene copy number and RNA expression analysis of the 17q12-23 region in primary breast cancers. Genes Chromosomes Cancer 2003;36(4):382-392. (Pubitemid 36314521)
30. Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, Tom E, Mack DH, Levine AJ. The transcriptional program following p53 activation. Cold Spring Harb Symp Quant Biol 2000;65:475-482. (Pubitemid 32611971)
31. TaylorMW, Tsukahara T, McClintick JN, Edenberg HJ, Kwo P. Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment. J Transl Med 2008;6:66-74.
32. Diegelmann J, Beigel F, Zitzmann K, Kaul A, Goke B, Auernhammer CJ, Bartenschlager R, Diepolder HM, Brand S. Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. PLoS One 2010;5(12): e15200.
33. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011;472:481-485.
34. Jaiswal S, Chao MP, Majeti R, Weissman IL. Macrophages as mediators of tumor immunosurveillance. Trends Immunol 2010;31(6):212-219.
35. Tang Y, Zhong G, Zhu L, Liu X, Shan Y, Feng H, Bu Z, Chen H, Wang C. Herc5 attenuates influenza A virus by catalyzing ISGylation of viral NS1 protein. J Immunol 2010;184(10): 5777-5790.
36. Hochrainer K, Mayer H, Baranyi U, Binder B, Lipp J, Kroismayr R. The human HERC family of ubiquitin ligases: Novel members, genomic organization, expression profiling, and evolutionary aspects. Genomics 2005;85(2):153-164. (Pubitemid 40164781)
37. Hochrainer K, Kroismayr R, Baranyi U, Binder BR, Lipp J. Highly homologous HERC proteins localize to endosomes and exhibit specific interactions with hPLIC and Nm23B. Cell Mol Life Sci 2008;65(13):2105-2117.
38. Patterson JB, Thomis DC, Hans SL, Samuel CE. Mechanism of interferon action: Double-stranded RNA-specific adenosine deaminase from human cells is inducible by alpha and gamma interferons. Virology 1995;210(2):508-511.
39. Hallen LC, Burki Y, Ebeling M, Broger C, Siegrist F, Oroszlan-Szovik K, Bohrmann B, Certa U, Foser S. Antiproliferative activity of the human IFN-alpha-inducible protein IFI44. J Interferon Cytokine Res 2007;27(8): 675-680. (Pubitemid 350194564)
40. Hartig SM, He B, Long W, Buehrer BM, Mancini MA. Homeostatic levels of SRC-2 and SRC-3 promote early human adipogenesis. J Cell Biol 2011;192(1):55-67.
41. Kimura O, Takahashi T, Ishii N, Inoue Y, Ueno Y, Kogure T, Fukushima K, Shiina M, Yamagiwa Y, Kondo Y, Inoue J, Kakazu E, Iwasaki T, Kawagishi N, Shimosegawa T, Sugamura K. Characterization of the epithelial cell adhesion molecule (EpCAM)+ cell population in hepatocellular carcinoma cell lines. Cancer Sci 2010;101(10):2145-2155.
42. Choudhury M, Qadri I, Rahman SM, Schroeder-Gloeckler J, Janssen RC, Friedman JE. C/EBPbeta is AMP kinase sensitive and up-regulates PEPCK in response to ER stress in hepatoma cells. Mol Cell Endocrinol 2011;331(1):102-108.
43. Artero JM, Herrera EA, Valero PL, Martin Luengo F. Comparative study of 2 rapid techniques (DNA hybridization and chromatography) for the identification of Mycobacterium tuberculosis complex isolated from clinical specimens. Enferm Infecc Microbiol Clin 1990;8(8):505-507.
44. Liebermann DA, Hoffman B. Gadd45 in stress signaling. J Mol Signal 2008;3:15-23.
45. Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 2010; 40(2):294-309.
46. Keyse SM, Emslie EA. Oxidative stress and heat shock induce a human gene encoding a protein-tyrosine phosphatase. Nature 1992;359(6396):644-647.
47. Behari J. The Wnt/beta-catenin signaling pathway in liver biology and disease. Expert Rev Gastroenterol Hepatol 2010; 4(6):745-756.
48. Melen K, Keskinen P, Ronni T, Sareneva T, Lounatmaa K, Julkunen I. Human MxB protein, an interferon-alphainducible GTPase, contains a nuclear targeting signal and is localized in the heterochromatin region beneath the nuclear envelope. J Biol Chem 1996;271(38):23478-23486. (Pubitemid 26314799)
49. Breslow DK, Collins SR, Bodenmiller B, Aebersold R, Simons K, Shevchenko A, Ejsing CS, Weissman JS. Orm family proteins mediate sphingolipid homeostasis. Nature 2010; 463(7284):1048-1053.
50. Moreno-Otero R. Therapeutic modalities in hepatitis C: Challenges and development. J Viral Hepat 2005;12(1): 10-19. (Pubitemid 40188769)
51. Abe H, Hayes CN, Ochi H, Maekawa T, Tsuge M, Miki D, Mitsui F, Hiraga N, Imamura M, Takahashi S, Kubo M, Nakamura Y, Chayama K. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol 2011; 54:1094-1101.
52. Rallon NI, Soriano V, Naggie S, Restrepo C, Goldstein D, Vispo E, McHutchison J, Benito JM. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C viruscoinfected patients treated with pegylated interferon and ribavirin. AIDS 2011; 25:1025-1033.
53. Lin E, Hwang Y, Chen EY. Gene-gene and gene-environment interactions in interferon therapy for chronic hepatitis C. Pharmacogenomics 2007;8(10):1327-1335. (Pubitemid 350167101)
54. Kaur S, Martin-Manso G, Pendrak ML, Garfield SH, Isenberg JS, Roberts DD. Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J Biol Chem 2010;285(50):38923-38932.
55. Wang H, VerHalen J, Madariaga ML, Xiang S,Wang S, Lan P, Oldenborg PA, Sykes M, Yang YG. Attenuation of phagocytosis of xenogeneic cells by manipulating CD47. Blood 2007;109(2):836-842. (Pubitemid 46105989)
56. Yoon SM, Gerasimidou D, Kuwahara R, Hytiroglou P, Yoo JE, Park YN, Theise ND. Epithelial cell adhesion molecule (EpCAM) marks hepatocytes newly derived from stem/ progenitor cells in humans. Hepatology 2011;53(3):964-973.
57. Xu Y, Johansson M, Karlsson A. Human UMP-CMP kinase 2, a novel nucleoside monophosphate kinase localized in mitochondria. J Biol Chem 2008;283(3):1563-1571.
58. Zlotnik A, Yoshie O, Nomiyama H. The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol 2006;7(12):243-252.
59. Sallusto F, Lanzavecchia A. Heterogeneity of CD4+ memory T cells: Functional modules for tailored immunity. Eur J Immunol 2009;39(8):2076-2082.
60. Zeremski M, Hooker G, Shu MA, Winkelstein E, Brown Q, Des Jarlais DC, Tobler LH, Rehermann B, Busch MP, Edlin BR, Talal AH. Induction of CXCR3-and CCR5-associated chemokines during acute hepatitis C virus infection. J Hepatol 2011; In press.
61. Casrouge A, Decalf J, Ahloulay M, Lababidi C, Mansour H, Vallet-Pichard A, Mallet V, Mottez E, Mapes J, Fontanet A, Pol S, Albert ML. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest 2011;121(1):308-317.
62. Guerrero-Preston R, Siegel A, Renz J, Vlahov D, Neugut A. HCV infection and cryptogenic cirrhosis are risk factors for hepatocellular carcinoma among Latinos in New York City. J Commun Health 2009;34(6):500-505.
63. Castello G, Costantini S, Scala S. Targeting the inflammation in HCV-associated hepatocellular carcinoma: A role in the prevention and treatment. J Transl Med 2010;8:109-115.
64. Zhang Z, Bryan JL, DeLassus E, Chang LW, Liao W, Sandell LJ. CCAAT/Enhancer-binding protein b and NF-kB mediate high level expression of chemokine genes CCL3 and CCL4 by human chondrocytes in response to IL-1b. J Biol Chem 2010; 285(43):33092-33103.
65. Mosbruger TL, Duggal P, Goedert JJ, Kirk GD, Hoots WK, Tobler LH, Busch M, Peters MG, Rosen HR, Thomas DL, Thio CL. Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus. J Infect Dis 2010;201(9): 1371-1380.
66. Tommerup N, Vissing H. Isolation and fine mapping of 16 novel human zinc finger-encoding cDNAs identify putative candidate genes for developmental and malignant disorders. Genomics 1995;27(2):259-264.
67. Chen YC, Zhang XW, Niu XH, Xin DQ, Zhao WP, Na YQ, Mao ZB. Macrophage migration inhibitory factor is a direct target of HBP1-mediated transcriptional repression that is overexpressed in prostate cancer. Oncogene 2010;29(21): 3067-3078.